8 Grines CL, Marsalese DL, Brodie B, et al. Safety and cost effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998; 31: 967–72. 9 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 339: 673–82. 10 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–23. 11 The Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–22. 12 Snijders TAB, Bosker RJ. Multilevel analysis: an introduction to basic and advanced multilevel modeling. London: Sage Publishers, 1999. 13 Sanz G, Betriu A, Oller G, et al. Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. J Am Coll Cardiol 1993; 22: 1795–801. 14 Newby LK, Eisenstein EL, Califf RM, et al. Cost-effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342: 749–55. 15 Dixon A, Mossialos E, eds. Health care systems in eight countries: trends and challenges. European Observatory on Health Care Systems. The London School of Economic and Political Science, 2002. 16 Ohman EM, Armstrong PW, Christenson RH, et al. for the GUSTOIIa Investigators. Cardiac Troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996; 335: 1333–41. 17 Ohman EM, Armstong PW, White HD, et al for the GUSTO-III Investigators. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. Am J Cardiol 1999; 84: 1281–86. 18 Stubbs P, Collinson P, Moseley D, et al. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circ 1996; 94: 1291–97. 19 Fu Y, Goodman S, Chang WC, et al. Time to treatment influences the impact of ST-segment resolution on one-year mortality: insights from the Assessment of the Safety of a New Thrombolytic Trial (ASSENT-2). Circ 2001; 104: 2653–2659. 20 Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358: 1571–75. 21 Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: A population-based comparison. J Am Coll Cardiol 1996; 27: 1335–42. ARTICLES